Blockchain Registration Transaction Record

Tonix Pharmaceuticals to Reveal TNX-801 Vaccine Data at Vaccine Congress 2025

Tonix Pharmaceuticals announces TNX-801 vaccine data at Vaccine Congress 2025, showcasing potential against mpox and orthopoxviruses. A leap in public health innovation.

The development of TNX-801 by Tonix Pharmaceuticals represents a critical advancement in vaccine technology, offering hope for effective protection against mpox and other orthopoxviruses. This is particularly relevant in a world increasingly faced with emerging viral threats. Additionally, Tonix's broader efforts in pain management and public health, including the potential FDA approval of TNX-102 SL for fibromyalgia, highlight the company's role in addressing some of today's most pressing health challenges. Their work not only has the potential to save lives but also to improve the quality of life for millions suffering from chronic conditions and infectious diseases.